2. Academic Validation
  3. Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells

Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells

  • Cancer Cell Int. 2022 Jan 31;22(1):50. doi: 10.1186/s12935-022-02471-8.
Fengqiang Sun 1,  Xiaomei Yu 2,  Ruixue Ju 1,  Zhanzhao Wang 1,  Yuhui Wang 3
Affiliations

Affiliations

  • 1 Department of Clinical Laboratory, Weifang People's Hospital, Weifang, 261000, Shandong, China.
  • 2 Department of Obstetrics, Weifang People's Hospital, Weifang, 261000, Shandong, China.
  • 3 Department of Clinical Laboratory, Weifang People's Hospital, Weifang, 261000, Shandong, China. [email protected].
PMID: 35101032 DOI: 10.1186/s12935-022-02471-8
Abstract

Background: Gastric Cancer (GC) has a poor prognosis and limited therapeutic options. As a new promising Cancer therapeutic approach, chimeric antigen receptor (CAR)-T cells represent a potential GC treatment. We investigated the antitumor activity of CAR-T cells target-B7H3 in GC.

Methods: In our study, expression of B7H3 was examined in GC tissues and explored the tumoricidal potential of B7H3-targeting CAR-T cells in GC. B7H3-directed CAR-T cells with a humanized antigen-recognizing domain was generated. The anti-tumor effects of this CAR-T cell were finally investigated in vitro and in vivo.

Results: Our results show that B7H3-directed CAR-T cells efficiently killed GC tumor cells. In addition, we found that B7H3 is correlated with tumor cell stemness, and anti-B7H3 CAR-T can simultaneously target stem cell-like GC cells to improve the treatment outcome.

Conclusions: Our study indicates that B7H3 is an attractive target for GC therapy, and B7H3 has high potential for clinical application.

Keywords

B7H3; CAR-T cell; Cancer stem cell; Clinical application; Gastric cancer.

Figures
Products